These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24572488)

  • 1. Analysis of thymidine kinase serum levels by novel method DiviTum in multiple myeloma and monoclonal gammopathy of undetermined significance - comparison with imaging methods 99mTc-MIBI scintigraphy and 18F-FDG PET/CT.
    Bacovsky J; Myslivecek M; Minarik J; Scudla V; Pika T; Zapletalova J; Petrova P; Bartkova M; Adam T; Gronowitz SJ
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Mar; 159(1):135-8. PubMed ID: 24572488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods].
    Myslivecek M; Bacovský J; Scudla V; Koranda P; Minarík J; Buriánková E; Formánek R; Zapletalová J
    Klin Onkol; 2010; 23(5):325-31. PubMed ID: 21061682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.
    Fonti R; Pace L; Cerchione C; Catalano L; Salvatore B; De Luca S; Pane F; Salvatore M; Del Vecchio S
    Clin Nucl Med; 2015 Apr; 40(4):303-8. PubMed ID: 25608167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
    Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
    Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DCE-MRI to distinguish all monoclonal plasma cell disease stages and correlation with diffusion-weighted MRI/PET-based biomarkers in a hybrid simultaneous whole body-2-[18F]FDG-PET/MRI imaging approach.
    Jamet B; Necib H; Carlier T; Frampas E; Bazin J; Desfontis PH; Monnet A; Bodet-Milin C; Moreau P; Touzeau C; Kraeber-Bodere F
    Cancer Imaging; 2024 Jul; 24(1):93. PubMed ID: 38992707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
    Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
    J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
    Ak I; Gulbas Z
    Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience.
    Sandecka V; Adam Z; Krejci M; Stork M; Rehak Z; Koukalova R; Sevcikova S; Brozova L; Kral Z; Mayer J; Pour L
    Neoplasma; 2020 Jul; 67(4):939-945. PubMed ID: 32567936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma.
    Okasaki M; Kubota K; Minamimoto R; Miyata Y; Morooka M; Ito K; Ishiwata K; Toyohara J; Inoue T; Hirai R; Hagiwara S; Miwa A
    Ann Nucl Med; 2015 Apr; 29(3):224-32. PubMed ID: 25421383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma.
    Mosci C; Pericole FV; Oliveira GB; Delamain MT; Takahashi MES; Carvalheira JBC; Etchebehere ECSC; Santos AO; Miranda ECM; Lima MCL; Amorim BJ; de Souza CA; Lorand-Metze I; Ramos CD
    Nucl Med Commun; 2020 Oct; 41(10):1081-1088. PubMed ID: 32732603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scintigraphy using (99m)Tc-MIBI (sestamibi), a sensitive parameter of activity of multiple myeloma.
    Bacovsky J; Scudla V; Myslivecek M; Nekula J; Vytrasová M
    Neoplasma; 2005; 52(4):302-6. PubMed ID: 16059646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.
    Bhutani M; Turkbey B; Tan E; Korde N; Kwok M; Manasanch EE; Tageja N; Mailankody S; Roschewski M; Mulquin M; Carpenter A; Lamping E; Minter AR; Weiss BM; Mena E; Lindenberg L; Calvo KR; Maric I; Usmani SZ; Choyke PL; Kurdziel K; Landgren O
    Leuk Lymphoma; 2016 May; 57(5):1114-21. PubMed ID: 26690712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
    Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
    Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tc 99m Sestamibi Scanning in Multiple Myeloma--a New look with SPECT-CT.
    Luthra K; Bhave A; Lele RD
    J Assoc Physicians India; 2014 Sep; 62(9):801-12. PubMed ID: 26259316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic relevance of 2-[
    Rudolphi-Solero T; Triviño-Ibáñez EM; González-Jiménez AD; Ramos-Font C; Ríos-Tamayo R; Rebollo-Aguirre AC; Sánchez-Sánchez R
    Hematol Oncol; 2023 Aug; 41(3):434-441. PubMed ID: 36222822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The "Undetermined Significance" of
    Treglia G; Bertagna F; Albano D
    Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?
    Spira D; Weisel K; Brodoefel H; Schulze M; Kaufmann S; Horger M
    Acad Radiol; 2012 Jan; 19(1):89-94. PubMed ID: 22142681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
    Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
    J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics.
    Mruck S; Baum RP; Rinne D; Hör G
    Anticancer Res; 1999; 19(4A):2685-90. PubMed ID: 10470220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The value of fluorodeoxyglucose positron emission tomography in multiple myeloma].
    Adam Z; Bolcák K; Stanícek J; Pour L; Hájek R; Krejcí M; Prásek J; Neubauer J; Mareschova Y; Vorlícek J
    Vnitr Lek; 2006 Mar; 52(3):207-14. PubMed ID: 16722151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.